ATE304846T1 - Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen - Google Patents

Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen

Info

Publication number
ATE304846T1
ATE304846T1 AT02719742T AT02719742T ATE304846T1 AT E304846 T1 ATE304846 T1 AT E304846T1 AT 02719742 T AT02719742 T AT 02719742T AT 02719742 T AT02719742 T AT 02719742T AT E304846 T1 ATE304846 T1 AT E304846T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
ibuprofen
organs
rejection reactions
Prior art date
Application number
AT02719742T
Other languages
German (de)
English (en)
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Application granted granted Critical
Publication of ATE304846T1 publication Critical patent/ATE304846T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT02719742T 2001-02-02 2002-01-30 Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen ATE304846T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (1)

Publication Number Publication Date
ATE304846T1 true ATE304846T1 (de) 2005-10-15

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719742T ATE304846T1 (de) 2001-02-02 2002-01-30 Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen

Country Status (26)

Country Link
US (1) US7560487B2 (https=)
EP (1) EP1355641B1 (https=)
JP (1) JP2004517948A (https=)
KR (1) KR100857898B1 (https=)
CN (1) CN1561205A (https=)
AT (1) ATE304846T1 (https=)
AU (1) AU2002250869B2 (https=)
BR (2) BR0206804A (https=)
CA (1) CA2432432C (https=)
CZ (1) CZ303665B6 (https=)
DE (1) DE60206245T2 (https=)
DK (1) DK1355641T3 (https=)
EE (1) EE05233B1 (https=)
ES (1) ES2248541T3 (https=)
HU (1) HU229070B1 (https=)
IL (1) IL157180A (https=)
IT (1) ITMI20010206A1 (https=)
MX (1) MXPA03006686A (https=)
NO (1) NO334285B1 (https=)
NZ (1) NZ526655A (https=)
PL (1) PL215109B1 (https=)
PT (1) PT1355641E (https=)
RU (1) RU2257895C2 (https=)
SK (1) SK287632B6 (https=)
WO (1) WO2002062330A2 (https=)
ZA (1) ZA200304861B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1579859E (pt) * 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
EP1883405A4 (en) 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
KR20150024919A (ko) * 2006-11-13 2015-03-09 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US20200003787A1 (en) * 2017-03-15 2020-01-02 Numares Ag Method for Using a Marker Set for Determining the Risk of Kidney Rejection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
RU2126262C1 (ru) * 1992-09-17 1999-02-20 Амген Боулдер Инк. Фармацевтическая композиция
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
EE200300340A (et) 2003-10-15
WO2002062330A2 (en) 2002-08-15
CA2432432A1 (en) 2002-08-15
DE60206245D1 (de) 2006-02-02
NO20033273D0 (no) 2003-07-18
DK1355641T3 (da) 2005-10-17
RU2257895C2 (ru) 2005-08-10
NO20033273L (no) 2003-07-18
KR20030074725A (ko) 2003-09-19
BRPI0206804B1 (pt) 2018-09-25
US7560487B2 (en) 2009-07-14
KR100857898B1 (ko) 2008-09-10
ZA200304861B (en) 2004-06-30
CZ303665B6 (cs) 2013-02-20
MXPA03006686A (es) 2004-05-31
WO2002062330A3 (en) 2003-04-03
PT1355641E (pt) 2005-11-30
ES2248541T3 (es) 2006-03-16
AU2002250869B2 (en) 2006-10-19
ITMI20010206A1 (it) 2002-08-02
NZ526655A (en) 2005-02-25
HUP0303024A2 (hu) 2003-12-29
NO334285B1 (no) 2014-01-27
EP1355641B1 (en) 2005-09-21
CA2432432C (en) 2008-03-25
DE60206245T2 (de) 2006-06-14
HUP0303024A3 (en) 2005-07-28
SK287632B6 (sk) 2011-04-05
PL215109B1 (pl) 2013-10-31
JP2004517948A (ja) 2004-06-17
EE05233B1 (et) 2009-12-15
PL363576A1 (en) 2004-11-29
CN1561205A (zh) 2005-01-05
RU2003126600A (ru) 2005-02-27
SK9732003A3 (en) 2003-11-04
BR0206804A (pt) 2004-02-03
EP1355641A2 (en) 2003-10-29
HU229070B1 (hu) 2013-07-29
IL157180A (en) 2009-06-15
CZ20032095A3 (en) 2004-05-12
US20040102520A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE60118604D1 (de) Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69914756D1 (de) Verwendung von isoosmotischen salzlösungen zur verhütung von entzündungen
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE304846T1 (de) Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
DE60313356D1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
NO972065D0 (no) Lagringsstabil vannopplösning for infusjon inneholdende en trombininhibitor
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE69900852D1 (de) Verwendung von isoosmotische salzlösungen zur herstellung von cerumenolytischer pharmazeutischer präparate
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
ATE521344T1 (de) Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
ATE232739T1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
DE502004006016D1 (de) Verwendung von Tolperison zur Behandlung von Spasmen von Organen, die im wesentlichen aus glatter Muskulatur aufgebaut sind.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355641

Country of ref document: EP

EEIH Change in the person of patent owner